Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Alvelestat

Generic Name: Alvelestat

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₂F_₃N_₅O_₄S

CAS Number: 848141-11-7

Unique Ingredient Identifier: 6Y5629322X

Overview

Alvelestat has been investigated for the basic science of Chronic Obstructive Pulmonary Disease.

Background

Alvelestat has been investigated for the basic science of Chronic Obstructive Pulmonary Disease.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

COVID-19 Study of Safety and Tolerability of Alvelestat

Phase 1

Completed

Posted: 2020/09/07

Sponsor:University of Alabam...

ID:NCT04539795

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Withdrawn

Posted: 2019/06/14

Sponsor:

Nelson Chao

ID:NCT03986086

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Phase 2

Completed

Posted: 2018/09/20

Sponsor:University of Alabam...

ID:NCT03679598

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

Phase 2

Completed

Posted: 2018/08/17

Sponsor:Mereo BioPharma

ID:NCT03636347

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Posted: 2016/02/01

Sponsor:National Cancer Inst...

ID:NCT02669251

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

GSK and iTeos Terminate TIGIT Cancer Drug Development After Phase 2 Failure

11 days ago

GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.

Mereo BioPharma's Setrusumab Shows Promise in Phase II, Alvelestat Gains EMA Orphan Status

4 months ago

Phase II results for setrusumab demonstrated significant improvements in fracture rates and bone strength, supporting continued development despite initial Phase III interim analysis outcomes.

Mereo BioPharma's Setrusumab Phase 3 Trial Progresses; Alvelestat Receives Positive EMA Opinion

6 months ago

Mereo BioPharma's setrusumab Phase 3 Orbit study for osteogenesis imperfecta is ongoing, with a second interim analysis expected in mid-2025.

Setrusumab Receives FDA Breakthrough Therapy Designation for Osteogenesis Imperfecta

6 months ago

The FDA granted Breakthrough Therapy Designation to setrusumab for reducing fracture risk in osteogenesis imperfecta (OI) types I, III, and IV, for patients aged 2 years and older.

Mereo BioPharma Advances Rare Disease Pipeline with Setrusumab and Alvelestat

a year ago

Mereo BioPharma's partner, Ultragenyx, anticipates completing enrollment for the Phase 3 Orbit study of setrusumab in Osteogenesis Imperfecta (OI) by the end of Q1 2024.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy